DNA-SWCNT Biosensors Allow Real-Time Monitoring of Therapeutic Responses in Pancreatic Ductal Adenocarcinoma.

TitleDNA-SWCNT Biosensors Allow Real-Time Monitoring of Therapeutic Responses in Pancreatic Ductal Adenocarcinoma.
Publication TypeJournal Article
Year of Publication2019
AuthorsBhattacharya, Santanu, Gong Xun, Wang Enfeng, Dutta Shamit K., Caplette Joseph R., Son Manki, Nguyen Freddy T., Strano Michael S., and Mukhopadhyay Debabrata
JournalCancer Res
Date Published2019 09 01
KeywordsAnimals, Antimetabolites, Antineoplastic, Biosensing Techniques, Carcinoma, Pancreatic Ductal, Deoxycytidine, Drug Monitoring, Female, Humans, Hydrogen Peroxide, Irinotecan, Luminescence, Mice, SCID, Nanotubes, Carbon, Pancreatic Neoplasms, Spectrum Analysis, Raman, Xenograft Model Antitumor Assays

Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic cancer with limited treatment options. There is an urgent need for tools that monitor therapeutic responses in real time. Drugs such as gemcitabine and irinotecan elicit their therapeutic effect in cancer cells by producing hydrogen peroxide (HO). In this study, specific DNA-wrapped single-walled carbon nanotubes (SWCNT), which precisely monitor HO, were used to determine the therapeutic response of PDAC cells and tumors . Drug therapeutic efficacy was evaluated by monitoring HO differences using reversible alteration of Raman G-bands from the nanotubes. Implantation of the DNA-SWCNT probe inside the PDAC tumor resulted in approximately 50% reduction of Raman G-band intensity when treated with gemcitabine versus the pretreated tumor; the Raman G-band intensity reversed to its pretreatment level upon treatment withdrawal. In summary, using highly specific and sensitive DNA-SWCNT nanosensors, which can determine dynamic alteration of hydrogen peroxide in tumor, can evaluate the effectiveness of chemotherapeutics. SIGNIFICANCE: A novel biosensor is used to detect intratumoral hydrogen peroxide, allowing real-time monitoring of responses to chemotherapeutic drugs.

Alternate JournalCancer Res
Refereed DesignationRefereed
PubMed ID31292162
PubMed Central IDPMC6726513
Grant ListR01 CA078383 / CA / NCI NIH HHS / United States
R01 CA150190 / CA / NCI NIH HHS / United States
R01 HL070567 / HL / NHLBI NIH HHS / United States
R29 CA078383 / CA / NCI NIH HHS / United States